Source-grounded facts extracted from ASPEN AEROGELS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ASPEN AEROGELS INC shareholders approved Non-binding advisory proposal regarding future declassification of the Board of Directors at the 2026-05-13 meeting.
“5. The Company’s stockholders approved, on a non-binding, advisory basis, a proposal regarding the future declassification of the Board of Directors, based on the following votes: For Against Abstain Broker Non-Votes 57,012,251 665,791 91,107 12,668,133”
ASPEN AEROGELS INC shareholders approved Non-binding advisory vote on frequency of holding advisory vote on executive compensation at the 2026-05-13 meeting.
“4. The Company’s stockholders approved, on a non-binding, advisory basis, a one-year frequency of holding an advisory vote on the compensation of the named executive officers, based on the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 56,316,979 34,117 1,316,984 101,069 12,668,133”
ASPEN AEROGELS INC shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-13 meeting.
“3. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting, based on the following votes: For Against Abstain Broker Non-Votes 49,538,581 7,344,203 886,365 12,668,133”
ASPEN AEROGELS INC shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-13 meeting.
“2. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstain Broker Non-Votes 69,845,522 571,148 20,612 -”
ASPEN AEROGELS INC shareholders approved Election of Class III directors at the 2026-05-13 meeting.
“1. The following nominees were elected to serve on the Board of Directors as Class III directors until the 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, based on the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Steven R. Mitchell 51,612,245 6,156,904 12,668,133 Donald R. Young 52,236,066 5,533,083 12,668,133”
Grant Thoele changed role as Principal Accounting Officer at ASPEN AEROGELS INC.
“On May 13, 2026, the Board of Directors of Aspen Aerogels, Inc. (the “Company”) designated Grant Thoele as the Company’s principal accounting officer, effective immediately, in addition to his current roles as the Company’s Chief Financial Officer, Treasurer and principal financial officer.”
ASPEN AEROGELS INC reported first quarter of 2026 results: revenue $37.9 million, net income Net loss was $23.7 million, EPS Net loss per share was $0.29.
“Total revenue for the first quarter of 2026 was $37.9 million, compared to $78.7 million in the prior year period.”
ASPEN AEROGELS INC amended Amendment No. 2 to Credit, Security and Guaranty Agreement with MidCap Funding IV Trust, as agent, MidCap Financial Trust, as term loan servicer, and the Lenders party thereto (effective 2025-12-16).
“are limited liability company (“ Aspen Mexico ”) and Aspen Aerogels Georgia, LLC, a Georgia limited liability company (“ Aspen Georgia ” and, together with the Company, Aspen RI and Aspen Mexico, collectively, the “ Credit Parties ”) entered into that certain Amendment No. 2 to Credit, Security and Guaranty Agreement (“ Amendment No. 2 ”), by and among the Credit Parties, MidCap Funding IV Trust, as agent (the “ Agent ”), MidCap Financial Trust, as term loan servicer (the “ Term Loan Servicer ”), and the Lenders (as defined below) party thereto, which amends that certain Credit, Security and Guaranty Agreement, dated as of August 19, 2024 (the “ Credit Agreement ” and the facilities provided thereunder, collectively, the “ MidCap Loan Facility ”; the MidCap Loan Facility, as amended by that certain Amendment No.”
ASPEN AEROGELS INC: Amended and restated Code of Business Conduct and Ethics adopted (effective 2024-11-14).
“On November 14, 2024, the Board of Directors of Aspen Aerogels, Inc. (the “Company”) approved and adopted an amended and restated Code of Business Conduct and Ethics (the “Code”), to replace the Company’s existing Code in its entirety, as part of its ordinary course review of the Company’s policies.”
Cari Robinson was appointed as Director at ASPEN AEROGELS INC.
“On August 14, 2024, the Board of Directors (the “Board”) of Aspen Aerogels, Inc. (the “Company”) appointed Cari Robinson to join the Board to serve as a Class I director until the Company’s 2027 Annual Meeting of Stockholders.”
ASPEN AEROGELS INC reported first quarter of 2024 results: revenue $94.5 million, net income Net loss was $1.8 million, EPS Net loss per share was $0.02. Guidance raised.
“Aspen Aerogels, Inc. Reports First Quarter 2024 Financial Results and Recent Business Highlights For Immediate Release $94.5 million in company revenue drove 37% gross profit margins and $12.9 million of Adjusted EBITDA Raising 2024 baseline Adjusted EBITDA outlook by 83% Expecting positive net income for 2024 NORTHBOROUGH, Mass., May 1, 2024 — Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Company”), a technology leader in sustainability and electrification solutions, today announced financial results for the first quarter of 2024, and discussed recent business developments. Total revenue for the first quarter of 2024 was $94.5 million, compared to $45.6 million in the first quarter of 2023. Net loss was $1.8 million, compared to a net loss of $16.8 million in the first quarter of 2023. Net loss per share was $0.02, compared to a net loss per share of $0.24 in the first quarter of 2023. Adjusted EBITDA for the first quarter of 2024 was $12.9 million, compared to $(13.9) million in”
ASPEN AEROGELS INC reported the fourth quarter and full year 2023, which ended December 31, 2023 results: revenue $238.7 million, net income Net loss for the year was $45.8 million, EPS Net loss per share for the year was $0.66.
“(EX-99.1) --- EX-99.1 Exhibit 99.1 Aspen Aerogels, Inc. Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Business Highlights For Immediate Release $84.2 million quarterly revenue enabled gross margins of 35% and adjusted EBITDA of $9.1 million NORTHBOROUGH, Mass., February 12, 2024 — Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the”
ASPEN AEROGELS INC reported full year 2023 results: revenue $238 million.
“2.02 of this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Aspen Aerogels, Inc. Provides Business Update Pre-Announces Full Year 2023 Revenues of $238 million; $84 million in Q4 Supplemental supply for Energy Industrial products initiated in Q4 Potential to Deliver Over 47% YoY revenue growth in 2024 NORTHBOROUGH, MA, January 11, 2023”
ASPEN AEROGELS INC entered into Securities Purchase Agreement with certain institutional investors valued at $12.375 per share (effective 2023-12-19).
“On December 19, 2023, Aspen Aerogels, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”) an aggregate of 6,060,607 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share.”
ASPEN AEROGELS INC: Amended and restated bylaws to update procedural mechanics and disclosure requirements for stockholder nominations and proposals, require universal proxy cards, and conform to current Delaware law (effective 2023-11-08).
“On November 8, 2023, the Board of Directors (the “Board”) of Aspen Aerogels, Inc. (the “Company”) approved the amendment and restatement of the Company’s Restated Bylaws (as amended and restated, the “Amended and Restated Bylaws”), which became effective immediately upon adoption.”
ASPEN AEROGELS INC reported the third quarter of 2023 results: revenue $60.8 million, net income $13.1 million, EPS $0.19.
“Total revenue for the third quarter of 2023 was $60.8 million, compared to $36.7 million in the third quarter of last year. Net loss was $13.1 million, compared to a net loss of $29.6 million in the third quarter of last year. Net loss per share was $0.19, compared to a net loss per share of $0.75 in the third quarter of last year.”
ASPEN AEROGELS INC amended Loan Agreement with General Motors Holdings LLC valued at Extended draw period to end on March 31, 2024; extended maturity date to September 30, 2025; added f (effective 2023-09-28).
“On September 28, 2023 (the “ First Amendment Effective Date ”), Aspen Aerogels Georgia, LLC, a Georgia limited liability company (the “ Borrower ”), a wholly-owned subsidiary of Aspen Aerogels, Inc., a Delaware corporation (the “ Company ”), entered into a first amendment (the “ First Amendment ”) to amend that certain loan agreement, dated as of November 28, 2022 (the “ Loan Agreement ”), by and among (i) the Borrower, (ii) the Company, as a guarantor and (iii) Aspen Aerogels Rhode Island, LLC, a Rhode Island limited liability company (“ Aspen RI ” and, together with the Borrower and the Company, each, a “ Loan Party ” and collectively, the “ Loan Parties ”), as a guarantor, and (iv) General Motors Holdings LLC (“ GM ”), as lender.”
Santhosh Daniel was appointed as Chief Accounting Officer at ASPEN AEROGELS INC.
“On September 14, 2023, Aspen Aerogels, Inc. (the “Company”) announced that on September 11, 2023, the Board of Directors (the “Board”) appointed Santhosh Daniel as its Chief Accounting Officer and principal accounting officer, effective as of September 13, 2023.”
ASPEN AEROGELS INC reported second quarter of 2023 results: revenue $48.2 million, net income $15.4 million, EPS $0.22. Guidance lowered.
“Total revenue for the second quarter of 2023 was $48.2 million, compared to $45.6 million in the second quarter of last year. Net loss was $15.4 million, compared to a net loss of $24.1 million in the second quarter of last year. Net loss per share was $0.22, compared to a net loss per share of $0.68 in the second quarter last year.”
ASPEN AEROGELS INC terminated Sales Agreement dated March 16, 2022 with Cowen and Company, LLC and Piper Sandler & Co. valued at Net proceeds of $72.7 million from sales of 5,241,400 shares under the 2022 ATM Offering Program; te (effective 2023-06-20).
“On June 15, 2023, Aspen Aerogels, Inc. (the “Company”), provided notice of its termination, effective June 20, 2023, of that certain Sales Agreement, dated as of March 16, 2022 (the “Sales Agreement”), by and among the Company, Cowen and Company, LLC (“Cowen”), and Piper Sandler & Co. (“Piper”).”
ASPEN AEROGELS INC: Stockholders approved amendments to the Certificate of Incorporation to add officer exculpation provisions under new Delaware law and to increase authorized common shares from 125,000,000 to 250,000,000 (effective 2023-06-01).
“The Amendments became effective upon the Company’s filing of a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of Delaware on June 1, 2023 (the “Certificate of Amendment”).”
ASPEN AEROGELS INC shareholders approved Approval of the Aspen Aerogels 2023 Equity Incentive Plan at the 2023-06-01 meeting.
“the Company’s stockholders approved the adoption of the Aspen Aerogels 2023 Equity Incentive Plan”
ASPEN AEROGELS INC reported the first quarter of 2023 results: revenue $45.6 million, net income $16.8 million, EPS $0.24. Guidance reaffirmed.
“Total revenue for the first quarter of 2023 was $45.6 million, compared to $38.4 million in the first quarter of last year. Net loss was $16.8 million, compared to a net loss of $19.5 million in the first quarter of last year. Net loss per share was $0.24, compared to a net loss per share of $0.59 in the first quarter last year.”
ASPEN AEROGELS INC reported the fiscal year 2022 results: revenue $180.4 million, net income $82.7 million, EPS $2.10.
“Total revenue for the full year was $180.4 million, compared to $121.6 million in 2021. Net loss for the year was $82.7 million, compared to a net loss of $37.1 million in 2021. Net loss per share for the year was $2.10, compared to $1.22 in 2021.”
ASPEN AEROGELS INC reported the fourth quarter of 2022 results: revenue $59.6 million, net income $9.6 million, EPS $0.20.
“Total revenue for the fourth quarter of 2022 was $59.6 million, compared to $31.5 million in the fourth quarter last year. Fourth quarter net loss was $9.6 million, compared to a net loss of $16.4 million in the fourth quarter of 2021. Net loss per share for the fourth quarter was $0.20, compared to $0.50 in the fourth quarter last year.”
ASPEN AEROGELS INC entered into Underwriting Agreement with Cowen and Company, LLC and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $240 million (effective 2022-11-29).
“On November 29, 2022, Aspen Aerogels, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Barclays Capital Inc., as representatives of the several underwriters named in Schedule A therein (the “Underwriters”), relating to the underwritten public offering of 25,263,158 shares of the Company’s common stock, par value $0.00001 per share (the “Offering”). The price to the public in the Offering was $9.50 per share.”
ASPEN AEROGELS INC incurred term loan of aggregate principal amount of up to $100.0 million with General Motors Holdings LLC at The interest rate on the Loan is equal to the term Secured Overnight Financing R maturing the earlier of (i) March 31, 2025 and (ii) 90 days prior to the maturity date of any other debt facility to which the Loan Parties may be a party (other than an.
“and equipment for the first phase of the Plant (the “ Budget ”). The Loan Agreement provides for a multi-draw senior secured term loan in an aggregate principal amount of up to $100.0 million (the “ Loan ”), available to the Borrower to draw on a delayed draw basis after January 1, 2023 to September 30, 2023, subject to certain conditions precedent to funding. The”
Kathleen M. Kool was appointed as Director at ASPEN AEROGELS INC.
“On November 1, 2022, the Board appointed Kathleen M. Kool to join the Board to serve as a Class II director until the 2025 Annual Meeting of Stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation, retirement or removal.”
Robert M. Gervis resigned as Director at ASPEN AEROGELS INC.
“On October 31, 2022, Robert M. Gervis, a member of the Board of Directors (the “Board”) of Aspen Aerogels, Inc. (the “Company”), notified the Company of his decision to resign from the Board, including as Chairperson of the Board’s Compensation and Leadership Development Committee and member of the Board’s Nominating, Governance and Sustainability Committee, effective as of 4:00 PM ET on Tuesday, November 1, 2022.”
ASPEN AEROGELS INC reported third quarter of 2022 results: revenue $36.7 million, net income $29.6 million, EPS $0.75.
“Total revenue for the third quarter of 2022 was $36.7 million, compared to $30.4 million in the third quarter last year. Third quarter net loss was $29.6 million, compared to a net loss of $7.8 million in the third quarter of 2021. Net loss per share for the third quarter was $0.75, compared to $0.24 in the third quarter last year.”
James E. Sweetnam was appointed as Class I director at ASPEN AEROGELS INC.
“On August 2, 2022, the Board of Directors (the “Board”) of Aspen Aerogels, Inc. (the “Company”) appointed James E. Sweetnam to join the Board to serve as a Class I director until the 2024 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, retirement or removal.”
Ricardo C. Rodriguez was appointed as Senior Vice President, Chief Financial Officer and Treasurer at ASPEN AEROGELS INC.
“Effective April 1, 2022, the Company promoted Ricardo C. Rodriguez, Chief Strategy Officer, to the position of Senior Vice President, Chief Financial Officer and Treasurer.”
John F. Fairbanks retired as Vice President, Chief Financial Officer and Treasurer at ASPEN AEROGELS INC.
“Mr. Fairbanks retired and resigned from his position as Vice President, Chief Financial Officer and Treasurer of the Company effective as of the Transition Date.”
Ricardo Rodriguez was appointed as Chief Financial Officer at ASPEN AEROGELS INC.
“In connection with Mr. Fairbanks’ retirement, the Company has announced that it intends to appoint Ricardo Rodriguez, Chief Strategy Officer of the Company, as Chief Financial Officer, effective April 1, 2022.”
John F. Fairbanks departed as Vice President, Treasurer and Chief Financial Officer at ASPEN AEROGELS INC.
“On January 13, 2022, John F. Fairbanks notified Aspen Aerogels, Inc. (the “Company”) of his intention to retire as Vice President, Treasurer and Chief Financial Officer of the Company, effective April 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.